Biotechnology News and Research

RSS

Nodality raises $15.5M to support launch of acute myelogenous leukemia test

Nodality, Inc., a biotechnology company focused on the development of next generation personalized medicine tests in cancer and autoimmune disease, today announced it completed financing in which the company raised $15.5 million.

23 Mar 2010

Advaxis' ADXS11-001 Phase 1 study for cervix cancer failures: 13.3% of treated patients alive at over 3 years

Ongoing follow up of the surviving patients from the phase I study of ADXS11-001 for the treatment of cervix cancer failures conducted by Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has shown that two of fifteen treated patients or 13.3% are still alive 1,248 and 1,128 days after receiving their initial dose.

23 Mar 2010

EHSI closes funding agreement with Celulas Genetica

Emerging Healthcare Solutions, Inc. announced today that it has closed its funding agreement with Celulas Genetica. EHSI will lock in up to 20% of earnings produced by Celulas Genetica when the agreement is funded in full.

22 Mar 2010

OSI Pharmaceuticals to redeem outstanding 3.25% Convertible Senior Subordinated Notes due 2023

OSI Pharmaceuticals, Inc. will fully redeem on April 21, 2010 all of its remaining outstanding 3.25% Convertible Senior Subordinated Notes due 2023 pursuant to the terms of the indenture under which the Notes were issued in September 2003. The aggregate principal amount currently outstanding of the Notes is $60,467,000. The CUSIP number for these Notes is 671040 AD 5.

22 Mar 2010

CRT, Cephalon to collaborate on development of small molecule inhibitors against cancer

Cancer Research Technology has announced an exclusive agreement with Cephalon, Inc., an international biotechnology company, to collaborate on the development of small molecule inhibitors. These molecules will target specific members of the 'protein kinase C' superfamily of cell signalling proteins - which have been shown to be associated with the development of cancer.

22 Mar 2010

ChemoCentryx undertakes Phase II clinical trial of CCX140

ChemoCentryx, Inc., today announced that it has undertaken a Phase II clinical trial of CCX140, a novel, orally-available small molecule compound designed to specifically target the chemokine receptor known as CCR2.

22 Mar 2010

First patient dosed in NCI-sponsored Phase 1/2 trial of belinostat

Spectrum Pharmaceuticals, Inc., a commercial-stage biotechnology company with a primary focus in oncology and hematology, and TopoTarget A/S, today announced that the first patient has been dosed in a National Cancer Institute -sponsored Phase 1/2 trial of belinostat in combination with cisplatin, doxorubicin and cyclophosphamide in the first line treatment of advanced or recurrent thymic malignancies.

22 Mar 2010

Acorda Therapeutics submits applications to extend patent protection for AMPYRA to USPTO

Acorda Therapeutics, Inc. today announced that the Company has submitted applications to extend patent protection for AMPYRA™ (dalfampridine) Extended Release Tablets, 10 mg to the United States Patent and Trademark Office.

22 Mar 2010

Vical awarded contract to conduct Phase 1 clinical trial of Vaxfectin-formulated DNA vaccine against A/H1N1

Vical Incorporated announced today that the U.S. Navy, through the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., has awarded Vical a contract to conduct a Phase 1 clinical trial of the company's Vaxfectin®-formulated DNA vaccine against A/H1N1 pandemic influenza (swine flu).

22 Mar 2010

iMDsoft's MetaVision suite of solutions to be distributed by Dominion in Spain

iMDsoft®, a global leader in hospital-wide clinical information systems, and Dominion, a leading provider of technology solutions in Spain and Latin America, have announced an agreement whereby Dominion will distribute iMDsoft's MetaVision® suite of solutions in Spain.

22 Mar 2010

Aston University scientists receive grants to develop new forms of drug delivery

Before you swallow a tablet, or put it into a glass of water to dissolve, do you ever stop and think about how it actually works in your body and how quickly and effectively it can deliver the drug to where it is needed?

22 Mar 2010

ILSI Biomed Israel 2010 international conference to be held in Tel Aviv

Set against the backdrop of the global market recovery and the recent proliferation of the life sciences field, this June’s ILSI Biomed Israel 2010 international conference will be attended by the most prominent figures in the biotechnology, pharma and medical device sectors.

22 Mar 2010

Tricking TB into suicidal self-poisoning

Scientists have identified a new class of drug target that tricks tuberculosis bacteria into suicidal self-poisoning. New therapies are urgently required to control the tuberculosis pandemic. Even in the UK cases are on the rise.

22 Mar 2010

Natural fibre in sea kelp may help tackle obesity

Seaweed could hold the key to tackling obesity after it was found it reduces fat uptake by more than 75 per cent, new research has shown.

22 Mar 2010

Nanotechnology weapons for cancer

US Researchers have come up with new nanoparticle robots that are essentially a tiny army that can travel in the blood till they reach the cancers and then tweak some important cancer causing genes that can cure the cancer.

22 Mar 2010

Passage of comprehensive health care reform: PhRMA issues statement

The Pharmaceutical Research and Manufacturers of America (PhRMA) issued the following statement today on passage of comprehensive health care reform and accompanying reconciliation legislation in the U.S. House of Representatives:

22 Mar 2010

‘Young Minds’ program for graduate and post-doctoral students

The Regenerative Medicine Foundation is pleased to announce a special "Young Minds" graduate student registration rate for its annual Translational Regenerative Medicine Forum, set for April 6-8 in Winston-Salem.

20 Mar 2010

New device detects bacterial and fungal contamination

Microorganisms are everywhere and most of them are harmless, but they can do a lot of damage in the manufacture of pharmaceuticals or in tissue transplants. With the aid of a new device, germs can be detected in artificial cartilage within a few hours.

20 Mar 2010

Akela Pharma files restated Management Discussion and Analysis for 2008 fiscal year

Akela Pharma, Inc., a leader in the development of therapeutics for the treatment of pain, and the company's wholly owned subsidiary, PharmaForm, today that it has today filed a restated Management Discussion and Analysis ("MD&A) for the fiscal year ended 2008.

20 Mar 2010

Impact of plastics on human health and ecosystems

Plastics surround us. A vital manufacturing ingredient for nearly every existing industry, these materials appear in a high percentage of the products we use every day. Although modern life would be hard to imagine without this versatile chemistry, products composed of plastics also have a dark side, due in part to the very characteristics that make them so desirable-their durability and longevity.

20 Mar 2010